- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- Rationale:
- The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers have concluded that the clear rationale to not evaluate these products is due to commissioning under the NHS England commissioning medicines for children in specialised services policy being appropriate with cabotegravir with rilpivirine being a paediatric extension of TA757. Please see eligibility criteria within the prioritisation manual for further information.
- ID number:
- 12219
Email enquiries
If you have any queries please email topic.selection@nice.org.uk
Related links
For further information on how we select topics for development, please see our page about topic prioritisation